Claims

1. A parenteral dosage form releasing an aromatase inhibitor in a daily release rate that does not induce stimulation of the ovaries by negative feed-back of the pituitary-ovarian-axis and a gestagen in a daily release rate below the ovulation inhibition dose but high enough to provide reliable contraceptive protection.

2. A dosage form of claim 1 in which the parenteral dosage form is a dosage form for local application.

3. A dosage form of either of the preceding claims in which the dosage form is selected from intravaginal ring, intrauterine device, subcutaneous implant or depot injection.

4. A dosage form of any of the preceding claims comprising one or more of the following aromatase inhibitors: anastrozole, exemestane, fadrozole, formestane, letrozole, pentrozole, vorozole or BGS649 and pharmaceutical acceptable salts thereof.

5. A dosage form of any of the preceding claims comprising one or more of the following gestagens: allylestrenol, chlormadinone acetate, cyproterone acetate, desogestrel, dienogest, drospirenone, dydrogesterone, etonogestrel, ethynodiol, gestodene, levonorgestrel, lynestrenol, medrogestone, medroxyprogesterone, megestrol acetate, nomegestrol, norethindrone, norethisterone, norethynodrel, norgestimate, norgestrel, quingestrone or trimegestone, and pharmaceutically acceptable salts thereof.

6. A dosage form of any of the preceding claims using anastrozole in combination with dienogest or anastrozole in combination with levonorgestrel or anastrozole in combination with gestodene.

7. A dosage form of any of the preceding claims in which the systemic anastrozole exposure achieved after release from the dosage form corresponds to the anastrozole exposure after oral administration in a dosage of less than 1 mg, or between 0.1 mg and 0.9 mg, of anastrozole per day, and which contains levonorgestrel, dienogest or gestodene as gestagen.

8. A dosage form of any of the preceding claims in which the systemic levonorgestrel exposure achieved after release from the IVR corresponds to the levonorgestrel exposure after oral administration in a dosage of more than 10 µg, but less than 50 µg, per day, and which contains the aromatase inhibitor anastrozole.

9. A dosage form of any of the preceding claims in which the systemic anastrozole exposure achieved after release from the dosage form corresponds to the anastrozole exposure after oral administration in a dosage of less than 1 mg, or between 0.1 mg and 0.9 mg, of anastrozole per day and the systemic levonorgestrel exposure achieved after release from the IVR corresponds to the levonorgestrel exposure after oral administration in a dosage of more than 10 µg, but less than 50 µg, per day.

10. A dosage form of any of claims 7, 8 and 9 in which the desired release rates claimed therein are achieved only one, two or three days after the start of treatment owing to the burst effect.

11. A dosage form of any of the preceding claims in which the aromatase inhibitor and the gestagen are delivered to the body via a controlled long-term release dosage form.

12. A dosage form of any of the preceding claims for treating endometriosis.

13. A dosage form of any of the preceding claims for treating endometriosis and for simultaneous contraception.

14. An IVR of any of the preceding claims.

15. An IVR of any of the preceding claims in which the long-term release period lasts from 1 week to 3 months.

16. An IVR of any of the preceding claims in which the long term release period lasts from 4 to 6 weeks.

17. An intrauterine device (IUD) of any of claims 1 to 13 in which the long term release period lasts at least 3 months.

18. An IUD of claim 17 in which the long term release period lasts one year or longer.

Claims

1. Intravaginal ring for treating endometriosis containing Anastrozole and Levonorgestrel , in which the systemic anastrozole exposure achieved after release from the dosage form corresponds to the anastrozole exposure after oral administration in a dosage of less than 1 mg, or between 0.1 mg and 0.9 mg, of anastrozole per day, under the proviso that no estrogen is contained in the intravaginal ring.

2. A dosage form of claim 1 in which the systemic levonorgestrel exposure achieved after release from the IVR corresponds to the levonorgestrel exposure after oral administration in a dosage of more than 10 µg, but less than 50 µg, per day.

3. A dosage form of any of the preceding claims in which the desired release rates claimed therein are achieved only one, two or three days after the start of treatment owing to the burst effect.

4. An IVR of any of the preceding claims in which the long-term release period lasts from 1 week to 3 months.

5. An IVR of any of the preceding claims in which the long term release period lasts from 4 to 6 weeks.